GH Research PLC
GHRSHealthcare|Biotechnology|Ireland
$26.67
-0.74 (-2.72%)
Tangible Book
$4.24
Earnings Power
$4.29
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06511947 Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects | Healthy Volunteers | P1 | Recruiting | 52 | Open-label | 5 Methoxy N,N Dimethyltryptamine |
| NCT05800860 A Trial of GH001 in Patients With Treatment-resistant Depression | Treatment-resistant Depression | P2 | Completed | 81 | RCT, Double-blind | GH001, Placebo |
| NCT04698603 Clinical Study of GH001 in Depression | Treatment Resistant Depression, Major Depressive Disorder | P1P2 | Completed | 16 | Open-label | 5 Methoxy N,N Dimethyltryptamine |
| NCT05804708 Phase 2 Clinical Trial of GH001 in Postpartum Depression | Postpartum Depression, Postnatal Depression | P2 | Terminated | 10 | Open-label | GH001 |
| NCT05839509 Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | Bipolar II Disorder | P2 | Terminated | 6 | Open-label | GH001 |
| NCT05163691 Pharmacokinetics of GH001 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 46 | RCT, Double-blind | 5 Methoxy N,N Dimethyltryptamine, Placebo |
| NCT05753956 Safety and Pharmacokinetics of GH002 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 64 | RCT, Double-blind | 5 Methoxy N,N Dimethyltryptamine, Placebo |
| NCT07540494 Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects | Healthy Adult | P1 | Not Yet Recruiting | 12 | Open-label | 5 Methoxy N,N Dimethyltryptamine |
| NCT04640831 Safety of GH001 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 22 | Open-label | 5 Methoxy N,N Dimethyltryptamine |